Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine

01-01-2010 | Case Report

Incidental finding of an 11C-acetate PET-positive multiple myeloma

Published in: Annals of Nuclear Medicine | Issue 1/2010

Login to get access

Abstract

Multiple myeloma is a malignancy of plasma cells. The 18F-FDG PET findings of multiple myeloma have been reported previously. However, the 11C-acetate PET findings have not been clarified. Here, we report a case of multiple myeloma detected with 11C-acetate PET in a 51-year-old male patient with known hepatocellular carcinoma. The patient was admitted for management of a pathologic fracture of the right tibia. Imaging workup including X-ray, magnetic resonance image, bone scintigraphy; 18F-FDG led to a suspicion of metastatic bony lesions. Further, these lesions showed increased uptake on 11C-acetate PET. Wide excision of the right tibia was performed, and histopathological examination of the lesion confirmed multiple myeloma. This case illustrates the characteristic 11C-acetate PET findings of multiple myeloma.
Literature
1.
Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol. 2002;31:690–4.CrossRefPubMed
2.
El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med. 1997;38:1208–10.PubMed
3.
Tirovola EB, Biassoni L, Britton KE, Kaleva N, Kouykin V, Malpas JS. The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer. 1996;74:1815–20.PubMed
4.
Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199–204.PubMed
5.
Cholewinski W, Castellon I, Raphael B, Heiba SI. Value of precise localization of recurrent multiple myeloma with F-18 FDG PET/CT. Clin Nucl Med. 2009;34:1–3.CrossRefPubMed
6.
Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68.CrossRefPubMed
7.
Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, et al. Multiple myeloma: molecular imaging with 11C-methionine PET/CT—initial experience. Radiology. 2007;242:498–508.CrossRefPubMed
8.
Roeda D, Dollé F, Crouzel C. An improvement of 11C acetate synthesis—non-radioactive contaminants by irradiation-induced species emanating from the 11C carbon dioxide production target. Appl Radiat Isot. 2002;57:857–60.CrossRefPubMed
9.
Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol. 1999;106:35–9.CrossRefPubMed
10.
Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104:723–9.CrossRefPubMed
11.
Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol. 1995;91:658–60.CrossRefPubMed
12.
Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457–63.PubMed
13.
Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol. 2004;72:32–7.CrossRefPubMed
14.
Vavere AL, Kridel SJ, Wheeler FB. Lewis JS.11C-acetate as PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49(21):327–34.CrossRefPubMed
15.
Abiko T, Koizumi S, Takanami I. Dual primary subclavicular angiosarcoma and lung cancer imaging with C-11 acetate PET and FDG PET. Clin Nucl Med. 2009;34:302–4.CrossRefPubMed
16.
Nomori H, Shibata H, Uno K, Iyama K, Honda Y, Nakashima R, et al. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma. J Thorac Oncol. 2008;3:1427–32.PubMed
17.
Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213–21.PubMed
18.
Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117–22.CrossRefPubMed
19.
Stjernholm RL. Carbohydrate metabolism in leukocytes. VII. Metabolism of glucose, acetate, and propionate by human plasma cells. J Bacteriol. 1967;93:1657–61.PubMed
Metadata
Title
Incidental finding of an 11C-acetate PET-positive multiple myeloma
Publication date
01-01-2010
Published in
Annals of Nuclear Medicine / Issue 1/2010
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0325-6